Latest European Market Entry News

Memphasys secures exclusive Felix™ commercialisation agreement in Poland, marking its third European market entry with a two-year contract valued at approximately A$350,000.

Streamplay Studio Limited has reported its fifth straight quarter of positive operating cash flow, driven by strong customer receipts and strategic publishing deals. The company is advancing multiple game releases and expanding its cloud gaming footprint across new regions.

AML3D Limited closed FY26 with a record $29 million order book, driven by US defence contracts and a $12 million investment to double its Ohio manufacturing capacity. The company’s cash receipts rose 20% to $10.4 million, while its sales pipeline expanded to $78 million.

4DMedical has leapfrogged into the European lung health market by acquiring Austrian AI imaging firm contextflow, gaining immediate commercial presence and a CE-marked lung cancer screening solution.

Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.

Orthocell’s latest Remplir™ Real World Evidence study reveals an 89.7% treatment success rate across 78 nerve repair procedures, reinforcing its clinical strength and fueling US and European market growth plans.

AML3D has maintained a steady $2.2 million quarterly revenue run rate and secured $12.5 million in new orders during 3Q26, pushing its total orders for FY2026 to $29 million. The company is aggressively expanding its US manufacturing footprint and making initial inroads into UK and European defence markets.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.

Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Iondrive Limited has joined a €3.1 million European battery recycling consortium backed by a German government grant, aiming to establish a closed-loop supply chain using its innovative DES technology.